Literature DB >> 7513734

Quantitation of endothelial cell specific protein E-9 employing a single monoclonal antibody in an indirect sandwich ELISA.

J M Wang1, P B Wilson, S Kumar, D Pye, R D Hunter.   

Abstract

An indirect enzyme-linked immunosorbent assay is described for the quantitation of protein E-9 which is specifically expressed on human vascular endothelial cells. The assay capitalizes on the dimeric structure of the E-9 protein by utilizing a single monoclonal antibody as both the capture and detection reagent. Detection is achieved by conjugating the Mab with biotin and is followed by the addition of streptavidin peroxidase to provide high sensitivity. Bound activity is measured by enhanced chemiluminescence utilizing standard Amerlite chemistry. The optimised assay is reproducible and is highly sensitive. Using this assay it was possible to detect the presence of E-9 protein in tissue culture media of endothelial cells and in serum samples--in one case even at 1/100 dilution. In vitro, X irradiation resulted in a greater than two-fold increase (P < or = 0.005) in the level of E-9 protein in culture supernatants of human umbilical vein endothelial cells (HUVEC). There are potential applications for measurements of E-9 protein in body fluids and tissue extracts from patients with a vast variety of diseases characterised by vascular endothelial damage and/or activation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7513734     DOI: 10.1016/0022-1759(94)90228-3

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  2 in total

1.  Endoglin is a novel endothelial cell specification gene.

Authors:  Saswati Banerjee; Sujoy K Dhara; Methode Bacanamwo
Journal:  Stem Cell Res       Date:  2011-08-27       Impact factor: 2.020

2.  Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin.

Authors:  O E Olsen; K F Wader; K Misund; T K Våtsveen; T B Rø; A K Mylin; I Turesson; B F Størdal; S H Moen; T Standal; A Waage; A Sundan; T Holien
Journal:  Blood Cancer J       Date:  2014-03-21       Impact factor: 11.037

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.